Samsung Biologics Signs $262 Million Manufacturing Agreement with European Pharma Firm
Samsung Biologics reported that it has inked a $262 million manufacturing agreement with an unnamed European pharmaceutical company. The deal includes manufacturing commitments, which will be conducted at Samsung Biologics’ Songdo manufacturing site in South Korea extending through 2033.
A Samsung Biologics’ spokesperson stated that the company’s cumulative contract value surpasses $21.9 billion following the latest agreement.
The company currently operates 845 kL of manufacturing capacity across Korea and the U.S., including 785 kL in Songdo and 60 kL at its Rockville, MD site. Acquired in March 2026, the Rockville facility established Samsung Biologics’ first manufacturing presence in the U.S., expanding the company’s global production network. Officials at Samsung Biologics say the company is also strengthening its regional presence through offices in NJ, Boston, Tokyo, and Amsterdam.
Samsung has secured land for Bio Campus III, establishing the foundation for its next phase of long-term capacity and capability expansion. The planned campus is expected to support dedicated R&D and manufacturing programs for next-generation therapeutics while the company continues to evaluate additional capacity investments in line with long-term market demand and client requirements.
Alongside capacity expansion, Samsung Biologics announced that it is pursuing opportunities to broaden its portfolio and address an increasingly diverse range of therapeutic modalities. The company has announced an all-cash offer to acquire PolyPeptide Group, which is expected to expand Samsung Biologics’ capabilities into peptide-based therapeutics and further diversify its global manufacturing network, subject to the completion of the proposed transaction.
NewsResearch and developmentTherapeuticsPolyPeptide GroupSamsung BiologicsPrevious article
Cancer Treatment Genetic Effects in Healthy Cells May Reveal Clues to Side Effects and ResistanceNext article
Transcenta Therapeutics and WuXi Biologics Team Up to Accelerate Commercialization of HiCB TechnologyAlso of Interest
Aprea Expands Development of WEE1 Inhibitor After Seeing Early Clinical Activity Signs vs. CancerCentrix and University of Sussex Collaborate to Drive Data-Driven Pharma DevelopmentStockWatch: Merck/Moderna Cancer Vaccine Gives a Shot in the Arm to Sequencing Companies, TooNext 10 U.S. Biopharma ClustersBMS Chooses Houston for $2.3B Manufacturing FacilityStockWatch: Lilly Rises on Revenue Leap; Analysts High on Krystal Despite Revenue MissRelated Media
AI in Protein Design: Hype vs. Reality Explained by David BakerCelebrating DNA: Matthew Cobb's Reflections on the Double HelixThe Sun Sets on AGBT: A Report from the Last DayGlobal Single-Use Network Support Assurance of SupplyReporter's Notebook: Opening Day at the J.P. Morgan Healthcare ConferenceResins Address Downstream Purification ConcernsTop 5ResourcesRecommended For YouPodcast
Touching Base
Touching Base is the dynamic podcast series from the editors ofGEN. Each episode features a rotating case of senior editors—including John Sterling, Kevin Davies, Julianna LeMieux, Alex Phillippidis, Uduak Thomas, Corinna Singleman, and Fay Lin—who delve into emerging stories, exchange ideas, and debate the latest trends in biotech. Additionally, they talk to some of the leading voices in the industry about what's now and next.Start listening today!
Stay up to date with the lasted episodes of Touching Base bysubscribing to theGENPodcast Newsletter